Entasis Therapeutics Holdings EBIT

Entasis Therapeutics Holdings (ETTX) currently reports a EBIT of $-87M as of March 2022. That compares with $-46M in the prior-year period — down 89.0% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Entasis Therapeutics Holdings's EBIT history and peer comparisons.

Entasis Therapeutics Holdings's EBIT decreased from $-46M to $-87M — a 89.0% year-over-year decrease (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Entasis Therapeutics Holdings's EBIT of $-87M is lower than the Healthcare sector average of $22B. That is roughly 100.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Entasis Therapeutics Holdings reported $-87M in EBIT as of March 2022. That compares with $-46M in the prior-year period — down 89.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-87M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Entasis Therapeutics Holdings, and consider following ETTX for alerts when major investors trade the stock.